Table 1 Pulmonary tumor cell adhesion in vivo
Treatment | Time intervall after cell injection [min] | |||
|---|---|---|---|---|
| Â | 0-10 | 11-20 | 21-30 | 31-40 |
|  | adherent cells/20 microscopic fileds [mean ± SD] | |||
T 84 control IgG [n = 6] | 16.7 ± 9.0 | 15.8 ± 5.1 | 14.1 ± 5.6 | 13.0 ± 1.9 |
HT-29 LMM control IgG [n = 9] | 13.5 ± 5.1 | 13.5 ± 4.8 | 11.1 ± 2.7 | 13.5 ± 2.3 |
anti integrin-β1 [n = 7] | 11.4 ± 4.7 | 11.8 ± 4.4 | 12.9 ± 2.7 | 12.3 ± 3.8 |
anti integrin-β4 [n = 10] | 13.4 ± 7.6 | 10.7 ± 4.0 | 10.4 ± 3.2 | 11.0 ± 4.5 |
anti integrin-αv [n = 8] | 10.6 ± 5.1 | 10.1 ± 4.1 | 9.5 ± 2.5 | 11.7 ± 2.7 |
vehicle [n = 12] | 12.8 ± 4.7 | 13.2 ± 6.7 | 10.9 ± 3.9 | 15.0 ± 5.9 |
neuraminidase type V [n = 8] | 7.4 ± 3.0 | 6.6 ± 2.3* | 6.5 ± 2.6* | 7.9 ± 2.9** |
fucoidane (animals) [n = 7] | 11.6 ± 6.9 | 7.4 ± 3.1* | 7.2 ± 3.3* | 5.6 ± 2.5** |
control medium [n = 5] | 10.9 ± 5.1 | 18.3 ± 10.1 | 16.4 ± 3.9 | 14.8 ± 6.1 |
anti galectin-3 [n = 5] | 18.8 ± 6.7 | 13.3 ± 2.4 | 13.1 ± 2.9 | 12.3 ± 3.2 |
anti TF [n = 4] | 11.5 ± 14.7 | 7.9 ± 4.7* | 8.6 ± 3.7** | 7.2 ± 4.0* |
anti TF + anti galectin-3 [n = 5] | 11.6 ± 1.0 | 7.4 ± 2.8** | 7.3 ± 2.3** | 6.5 ± 1.4** |